AgomAb Therapeutics NV (AGMB)

NASDAQ: AGMB · Real-Time Price · USD

9.08

-0.14 (-1.52%)

At close: Oct 9, 2026, 4:00 PM EDT

9.26

+0.18 (1.98%)

After-hours: Oct 9, 2026, 7:47 PM EDT

AgomAb Therapeutics NV Financials Overview

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
Gross Profit	-	-	-	-	-	-2.89
Operating Income	-65.94	-59.28	-48.02	-31.19	-22.63	-3.09
Net Income	-81.6	-77.5	-57.95	-19.28	-13.56	-3.05
Earnings Per Share	-3.95	-143.22	-107.09	-35.63	-25.07	-
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
Cash & Investments	251.98	116.51	171.46	122.4	67.67	7.33
Total Debt	1.14	1.25	1.55	1.62	0.06	-
Net Cash (Debt)	250.84	115.26	169.91	120.78	67.61	7.33
Net Cash Growth	-	-32.17%	40.68%	78.65%	822.76%	5771.49%
Net Cash Per Share	12.15	213.00	314.00	223.20	124.94	-

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
Operating Cash Flow	-56.73	-51.74	-46.83	-24.59	-18.97	-
Capital Expenditures	-0	-0	-0.68	-	-	-
Free Cash Flow	-56.73	-51.75	-47.5	-24.59	-18.97	-
Free Cash Flow Growth	-	-	-	-	-	-